Craft
Amarillo Biosciences

Amarillo Biosciences

Revenue

$594.6 K

FY, 2021

Market Capitalization

$25.2 M

2021-07-22

Amarillo Biosciences Summary

Company summary

Overview
Amarillo Biosciences (ABI) is a healthcare company that specializes in the discovery and development of novel biopharmaceuticals, medical treatments, and specialty consumer products. It is engaged in the clinical trials of low-dose oral interferon as a therapeutic treatment for thrombocytopenia, Sjögren's syndrome, hepatitis C virus (HCV), and influenza indications. In addition, the company develops a treatment to address metabolism related diseases such as T1 and T2 diabetes using a pulsatile insulin infusion therapy that mimics the normal pancreas’ functions.
Type
Public
Status
Active
Founded
1984
HQ
Amarillo, TX, US | view all locations
Website
http://amarbio.com/
Cybersecurity rating
Sectors

Key people

  • Stephen T. Chen
  • Bernard H. Cohen, Vice President

  • John Junyong Lee, Corporate Legal Counsel

    • Yasushi Chikagami, Board Member

      LocationsView all

      2 locations detected

      • Amarillo, TX HQ

        United States

        4134 Business Park Dr

      • Taipei, Taipei City

        Taiwan

        7/F, No. 58, Sec 1, Minsheng East Road Zhongshan District

      Amarillo Biosciences Financials

      Summary financials

      Revenue (Q3, 2022)
      $1.8M
      Gross profit (Q3, 2022)
      $581.7K
      Net income (Q3, 2022)
      ($7.8M)
      Cash (Q3, 2022)
      $2.4M
      EBIT (Q3, 2022)
      ($7.8M)
      Enterprise value
      $24.1M

      Footer menu